Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2 V617F-allele burden in polycythemia vera

Abstract We report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the JAK2 V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib....

Full description

Saved in:
Bibliographic Details
Published inLeukemia research reports Vol. 3; no. 2; pp. 73 - 75
Main Authors Bjørn, M.E, de Stricker, K, Kjær, L, Ellemann, K, Hasselbalch, H.C
Format Journal Article
LanguageEnglish
Published 2014
Subjects
Hematology, Oncology and Palliative Medicine
Pathology
Ruxolitinib
Polycythemia vera
Interferon
Combination therapy
JAK2V617F-allele burden
Online AccessGet full text

Cover

More Information
Summary:Abstract We report a 55 year old woman with post-ET PV for 12 years, who experienced resolution of severe constitutional symptoms within 3 days, a marked reduction in splenomegaly and a rapid decline in the JAK2 V617F allele burden during combination therapy with interferon-alpha2a and ruxolitinib. Within 4 weeks the patient achieved complete hematological remission with normalization of peripheral blood counts and within 10 months the JAK2 V617F-allele burden was reduced from 90% to 28%. Such a rapid decline in the JAK2 V617F allele burden is highly unusual in PV-patients during low-dose IFN-alpha2 monotherapy and this finding warrants a prospective study with combination therapy.
ISSN:2213-0489
2213-0489
DOI:10.1016/j.lrr.2014.05.003